Related Experiment Video
Updated: Oct 19, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone
1Department of Oncology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.
Abstract:
We have previously demonstrated that halofuginone, a widely used alkaloid coccidiostat, is a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 gene expression. Halofuginone also suppresses extracellular matrix deposition and cell proliferation. We investigated the effect of halofuginone on transplantable and chemically induced mouse bladder carcinoma. In both systems, oral administration of halofuginone resulted in a profound anticancerous effect, even when the treatment was initiated at advanced stages of tumor development. Although halofuginone failed to prevent proliferative preneoplastic alterations in the bladder epithelium, it inhibited further progression of the chemically induced tumor into a malignant invasive stage. Histological examination and in situ analysis of the tumor tissue revealed a marked decrease in blood vessel density and in both collagen alpha1(I) and H19 gene expression. H19 is regarded as an early marker of bladder carcinoma. The antiangiogenic effect of halofuginone was also demonstrated by inhibition of microvessel formation in vitro. We attribute the profound antitumoral effect of halofuginone to its combined inhibition of the tumor stromal support, vascularization, invasiveness, and cell proliferation.
Insights
Halofuginone, an alkaloid coccidiostat, significantly inhibits bladder carcinoma growth by suppressing tumor vascularization, collagen deposition, and cell proliferation. This drug shows potent anticancer effects even in advanced stages of the disease.
Area of Science:
- Oncology
- Pharmacology
- Biochemistry
Background:
- Halofuginone is a known inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 gene expression.
- It also suppresses extracellular matrix deposition and cell proliferation.
- Previous studies demonstrated halofuginone's inhibitory effects on specific gene expressions and cellular processes.
Purpose of the Study:
- To investigate the anticancerous effect of halofuginone on transplantable and chemically induced mouse bladder carcinoma.
- To evaluate halofuginone's impact on tumor progression, vascularization, and key gene expressions in bladder cancer models.
Main Methods:
- Oral administration of halofuginone in mouse models of bladder carcinoma.
- Histological examination and in situ analysis of tumor tissues.
- In vitro assessment of halofuginone's antiangiogenic properties by measuring microvessel formation.
Main Results:
- Oral halofuginone demonstrated a profound anticancerous effect in both transplantable and chemically induced mouse bladder carcinoma models.
- Treatment inhibited tumor progression to invasive stages and reduced blood vessel density.
- Significant downregulation of collagen alpha1(I) and H19 gene expression was observed in tumor tissues.
Conclusions:
- Halofuginone exhibits significant antitumoral effects in mouse bladder carcinoma models.
- The drug's efficacy is attributed to its combined inhibition of tumor stromal support, vascularization, invasiveness, and cell proliferation.
- Halofuginone displays antiangiogenic properties, making it a potential therapeutic agent for bladder cancer.
